Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01877382
Other study ID # DS3032-A-U101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 2013
Est. completion date December 3, 2020

Study information

Verified date December 2020
Source Daiichi Sankyo, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a Phase 1, open-label study of milademetan to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic (PK)/ pharmacodynamic (PDy) properties in participants with advanced solid tumors or lymphomas. Approximately 5 US sites are planned for Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The same sites are planned to participate for both parts.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date December 3, 2020
Est. primary completion date October 8, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Dose Escalation Cohorts (Part 1) - Has a histologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment, or for which no standard treatment is available. - Participants with melanoma who are ineligible to receive or have declined ipilimumab treatment or who are refractory or intolerant to ipilimumab may enroll. - Participants with certain tumor types such as those with high prevalence of MDM2 amplification or overexpression (eg, well-differentiated [WD]/dedifferentiated [DD] liposarcoma) may be preferentially enrolled in Part 1. Dose Expansion Cohort (Part 2) - Has a histologically or cytologically documented advanced melanoma or diffuse large B cell lymphoma (DLBCL), with measurable disease that is refractory to standard treatment or for which no standard treatment is available. - Participants with melanoma who are ineligible to receive or have declined ipilimumab treatment or who are refractory or intolerant to ipilimumab may enroll. - Participants with DLBCL who have failed, been deemed ineligible for, or refused autologous stem cell transplantation may enroll. - Man or woman = 18 years old. - Has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1. - Has adequate bone marrow function, defined as: - Platelet count = 100 x 10^9/L - Hemoglobin = 9.0 g/dL - Absolute neutrophil count = 1.5 x 10^9/L. - Has adequate renal function, defined as creatinine clearance = 60 mL/min, as calculated using the modified Cockcroft Gault equation, ([{140 - age in years} × {actual weight in kg}] divided by [{72 × serum creatinine in mg/dL} multiply by 0.85 if female]), OR creatinine = 1.5 x ULN. - Has adequate hepatic function, defined as: - AST/ALT levels = 3 x ULN (if liver metastases are present, = 5 x ULN) - Bilirubin = 1.5 x ULN. - Has adequate blood clotting function, defined as International normalized ratio (INR) and activated partial thromboplastin time (aPTT) = 1.5 x ULN. - Participant should be able to provide written informed consent, comply with protocol visits and procedures, be able to take oral medication, and not have any active infection or comorbidity that would interfere with therapy. - Participant (male and female) of childbearing/reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug. - Participant must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IRB [Institutional Review Board]-approved Informed consent Form [ICF] (including Health Insurance Portability and Accountability Act authorization, if applicable) before performance of any study specific procedures or tests. - Is willing to provide and there is confirmed availability of pre-existing diagnostic or resected tumor samples, such as paraffin-embedded sections. Providing fresh tumor biopsy is optional for participants in Dose Escalation cohorts. - Is willing to undergo tumor genotyping for TP53 mutation, insertion, or deletion at screening. Confirmation of TP53 nonmutant status is encouraged, but not required prior to milademetan dosing. - Is willing to provide additional archived samples for comprehensive genomic and/or proteomic analyses if the participant has a partial response/complete response to milademetan treatment. - Is willing to undergo pre-treatment tumor biopsies (Part 2 only) Exclusion Criteria: - Has a tumor that contains an inactivating mutation, insertion, or deletion in the TP53 gene determined previously or at screening. - Has a history of primary central nervous system malignancy. - Has gastrointestinal conditions that could affect the absorption of milademetan in the opinion of the Investigator. - Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection. - Has received an allogeneic bone marrow or allogeneic stem cell transplant. - Has a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor. - Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 4 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (2 weeks for stereotactic radiotherapy). - Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v4, grade = 1 or baseline. Participants with chronic grade 2 toxicities may be eligible per the discretion of the Investigator and Sponsor (eg, grade 2 chemotherapy-induced neuropathy). - Had an autologous transplant within 3 months of starting study drug treatment. - Is receiving concomitant treatment with a strong inducer of CYP3A. - Had systemic treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or treatment with small-molecule targeted agents within 2 weeks before study drug treatment. Previous and concurrent use of hormone replacement therapy, the use of gonadotropin releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 8 weeks before study drug treatment. - Had therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment. - Participated in a therapeutic clinical study within 3 weeks before study drug treatment, or current participation in other therapeutic investigational procedures. - Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 milliseconds (ms) for males and > 470 ms for females based on triplicate ECG. - Pregnant or breastfeeding. - Substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the participant's participation in the clinical study or evaluation of the clinical study results. - Prior treatment with an MDM2 inhibitor.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Milademetan
DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
Milademetan
Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.

Locations

Country Name City State
United States Karmanos Cancer Institute Detroit Michigan
United States UT MD Anderson Cancer Center Houston Texas
United States Tennessee Oncology Nashville Tennessee
United States Columbia University College of Physicians and Surgeons New York New York
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Daiichi Sankyo, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-emergent Adverse Events by Frequency and Grade in Each Cohort of Dose and Dosing Schedule and the Total Number of Participants With the Treatment-emergent Adverse Events From start of study until last subject last visit (approximately 6 years)
Primary Maximum Tolerated Dose(s) (MTD) Identified at Different Dosing Schedules From start of study until final database lock (approximately 6 years)
Primary Number of Participants With Dose-Limiting Toxicities at Each Dose Level [level/cohort] and the Total Number of Participants With Dose-limiting Toxicities From start of study until the dose-limiting toxicity evaluation of the last participant in dose escalation part (approximately 6 years or less)
Primary Number of Participants With Melanoma and Diffuse Large B Cell Lymphoma in Dose Expansion Cohorts Who Achieved Objective Response per RECIST v1.1 and International Working Group, Respectively From start of study until last tumor assessment in Dose Expansion (approximately 6 years)
Secondary Summary of Milademetan PK Parameter Maximum Plasma Concentration (Cmax) From start of study until final database lock (approximately 6 years)
Secondary Summary of Milademetan PK Parameter Area Under the Curve (AUC) From start of study until final database lock (approximately 6 years)
Secondary Summary of Milademetan PK Parameter Time to Reach Maximum Plasma concentration (Tmax) From start of study until final database lock (approximately 6 years)
Secondary Summary of Milademetan PK Parameter Apparent Clearance (CL/F) From start of study until final database lock (approximately 6 years)
Secondary Summary of Milademetan PK Parameter Elimination Terminal Half Life Half-Life (T1/2) From start of study until final database lock (approximately 6 years)
Secondary Pharmacodynamic Effect of Milademetan Assessed by Increase in Serum MIC-1 Levels Over Baseline From start of study until final database lock (approximately 6 years)
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1